Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LBPH NASDAQ:ROIV NASDAQ:RVMD NASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLBPHLongboard Pharmaceuticals$59.98$59.88$27.35▼$60.03$2.34B11.37 million shsN/AROIVRoivant Sciences$14.08-2.3%$11.86$8.73▼$14.48$9.84B1.156.26 million shs7.59 million shsRVMDRevolution Medicines$46.55+0.7%$37.94$29.17▼$62.40$8.64B1.121.87 million shs3.63 million shsVRNAVerona Pharma PLC American Depositary Share$106.43+0.0%$104.80$27.54▼$106.45$9.20B0.141.25 million shs918,692 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLBPHLongboard Pharmaceuticals0.00%0.00%0.00%0.00%+78.51%ROIVRoivant Sciences+4.65%+14.64%+24.55%+27.30%+16.40%RVMDRevolution Medicines+14.31%+18.72%+31.14%+13.92%+10.99%VRNAVerona Pharma PLC American Depositary Share+0.03%+0.15%+1.15%+15.40%+252.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLBPHLongboard Pharmaceuticals$59.98$59.88$27.35▼$60.03$2.34B11.37 million shsN/AROIVRoivant Sciences$14.08-2.3%$11.86$8.73▼$14.48$9.84B1.156.26 million shs7.59 million shsRVMDRevolution Medicines$46.55+0.7%$37.94$29.17▼$62.40$8.64B1.121.87 million shs3.63 million shsVRNAVerona Pharma PLC American Depositary Share$106.43+0.0%$104.80$27.54▼$106.45$9.20B0.141.25 million shs918,692 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLBPHLongboard Pharmaceuticals0.00%0.00%0.00%0.00%+78.51%ROIVRoivant Sciences+4.65%+14.64%+24.55%+27.30%+16.40%RVMDRevolution Medicines+14.31%+18.72%+31.14%+13.92%+10.99%VRNAVerona Pharma PLC American Depositary Share+0.03%+0.15%+1.15%+15.40%+252.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLBPHLongboard Pharmaceuticals 2.00Hold$62.804.70% UpsideROIVRoivant Sciences 3.50Strong Buy$17.6725.47% UpsideRVMDRevolution Medicines 3.07Buy$73.6758.25% UpsideVRNAVerona Pharma PLC American Depositary Share 2.14Hold$109.002.41% UpsideCurrent Analyst Ratings BreakdownLatest LBPH, VRNA, ROIV, and RVMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025RVMDRevolution MedicinesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$65.00 ➝ $73.009/12/2025RVMDRevolution MedicinesRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$72.009/11/2025RVMDRevolution MedicinesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$67.00 ➝ $70.009/11/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$73.00 ➝ $77.009/11/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $66.009/5/2025RVMDRevolution MedicinesTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$99.009/2/2025ROIVRoivant SciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight ➝ Buy$16.008/18/2025RVMDRevolution MedicinesPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$75.008/18/2025RVMDRevolution MedicinesLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$80.008/15/2025RVMDRevolution MedicinesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$67.008/8/2025VRNAVerona Pharma PLC American Depositary ShareZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLBPHLongboard PharmaceuticalsN/AN/AN/AN/A$1.67 per shareN/AROIVRoivant Sciences$29.05M330.98N/AN/A$7.45 per share1.89RVMDRevolution Medicines$11.58M751.43N/AN/A$13.47 per share3.46VRNAVerona Pharma PLC American Depositary Share$42.28M217.74N/AN/A$2.56 per share41.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLBPHLongboard Pharmaceuticals-$54.42M-$2.23N/AN/AN/AN/A-33.03%-30.90%N/AROIVRoivant Sciences-$171.98M-$0.70N/AN/AN/A-2,111.79%-15.90%-14.95%11/11/2025 (Estimated)RVMDRevolution Medicines-$600.09M-$4.50N/AN/AN/AN/A-41.78%-35.63%11/5/2025 (Estimated)VRNAVerona Pharma PLC American Depositary Share-$173.42M-$0.99N/A3,547.67N/A-36.62%-21.12%-9.07%11/3/2025 (Estimated)Latest LBPH, VRNA, ROIV, and RVMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025RVMDRevolution Medicines-$0.94-$1.31-$0.37-$1.31$0.50 millionN/A8/6/2025Q2 2025VRNAVerona Pharma PLC American Depositary Share-$0.01$0.13+$0.14$0.13$90.41 million$103.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLBPHLongboard PharmaceuticalsN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/AVRNAVerona Pharma PLC American Depositary ShareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLBPHLongboard PharmaceuticalsN/A15.9715.97ROIVRoivant SciencesN/A40.5440.54RVMDRevolution Medicines0.1311.7911.79VRNAVerona Pharma PLC American Depositary Share0.8710.7110.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLBPHLongboard Pharmaceuticals63.28%ROIVRoivant Sciences64.76%RVMDRevolution Medicines94.34%VRNAVerona Pharma PLC American Depositary Share85.88%Insider OwnershipCompanyInsider OwnershipLBPHLongboard Pharmaceuticals4.64%ROIVRoivant Sciences10.80%RVMDRevolution Medicines8.20%VRNAVerona Pharma PLC American Depositary Share4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLBPHLongboard Pharmaceuticals2039.05 million37.23 millionOptionableROIVRoivant Sciences860682.88 million609.13 millionOptionableRVMDRevolution Medicines250186.93 million171.60 millionOptionableVRNAVerona Pharma PLC American Depositary Share3086.50 million82.34 millionOptionableLBPH, VRNA, ROIV, and RVMD HeadlinesRecent News About These CompaniesVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Sets New 12-Month High - Should You Buy?September 12 at 10:22 AM | marketbeat.comHere’s What Boosted Verona Pharma plc (VRNA) Share Price by 49%September 12 at 8:51 AM | insidermonkey.comFred Alger Management LLC Lowers Holdings in Verona Pharma PLC American Depositary Share $VRNASeptember 12 at 5:20 AM | marketbeat.comVerona Pharma PLC American Depositary Share $VRNA Shares Sold by Octagon Capital Advisors LPSeptember 11 at 6:03 AM | marketbeat.comScientech Research LLC Takes Position in Verona Pharma PLC American Depositary Share $VRNASeptember 10 at 5:43 AM | marketbeat.comInvesco Ltd. Makes New Investment in Verona Pharma PLC American Depositary Share $VRNASeptember 10 at 3:02 AM | marketbeat.comTemasek Holdings Private Ltd Makes New $2.01 Million Investment in Verona Pharma PLC American Depositary Share $VRNASeptember 9 at 6:57 AM | marketbeat.comParkman Healthcare Partners LLC Decreases Holdings in Verona Pharma PLC American Depositary Share $VRNASeptember 8, 2025 | marketbeat.comPolar Asset Management Partners Inc. Takes Position in Verona Pharma PLC American Depositary Share $VRNASeptember 8, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share $VRNA Shares Acquired by Duquesne Family Office LLCSeptember 6, 2025 | marketbeat.comEventide Asset Management LLC Reduces Stake in Verona Pharma PLC American Depositary Share $VRNASeptember 6, 2025 | marketbeat.comCinctive Capital Management LP Purchases New Position in Verona Pharma PLC American Depositary Share $VRNASeptember 6, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share $VRNA Stake Raised by Boothbay Fund Management LLCSeptember 6, 2025 | marketbeat.com160,000 Shares in Verona Pharma PLC American Depositary Share $VRNA Bought by Cutter Capital Management LPSeptember 6, 2025 | marketbeat.comAllostery Investments LP Invests $794,000 in Verona Pharma PLC American Depositary Share $VRNASeptember 5, 2025 | marketbeat.comAlly Bridge Group NY LLC Buys Shares of 139,067 Verona Pharma PLC American Depositary Share $VRNASeptember 5, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Hits New 1-Year High - Here's What HappenedSeptember 5, 2025 | marketbeat.comState of Wyoming Invests $291,000 in Verona Pharma PLC American Depositary Share $VRNASeptember 5, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Boosts Position in Verona Pharma PLC American Depositary Share $VRNASeptember 4, 2025 | marketbeat.comADAR1 Capital Management LLC Cuts Stock Holdings in Verona Pharma PLC American Depositary Share $VRNASeptember 4, 2025 | marketbeat.comVestal Point Capital LP Sells 227,373 Shares of Verona Pharma PLC American Depositary Share $VRNASeptember 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLBPH, VRNA, ROIV, and RVMD Company DescriptionsLongboard Pharmaceuticals NASDAQ:LBPHLongboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.Roivant Sciences NASDAQ:ROIV$14.08 -0.33 (-2.29%) Closing price 04:00 PM EasternExtended Trading$14.04 -0.04 (-0.25%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Revolution Medicines NASDAQ:RVMD$46.55 +0.31 (+0.67%) Closing price 04:00 PM EasternExtended Trading$46.30 -0.25 (-0.54%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Verona Pharma PLC American Depositary Share NASDAQ:VRNA$106.43 +0.03 (+0.03%) Closing price 04:00 PM EasternExtended Trading$106.19 -0.24 (-0.23%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
